Novo Nordisk A/S (NVO) Analysts See $0.59 EPS

Novo Nordisk A/S (NYSE:NVO) Logo

Analysts expect Novo Nordisk A/S (NYSE:NVO) to report $0.59 EPS on February, 7.They anticipate $0.06 EPS change or 11.32 % from last quarter’s $0.53 EPS. NVO’s profit would be $1.42 billion giving it 20.57 P/E if the $0.59 EPS is correct. After having $0.58 EPS previously, Novo Nordisk A/S’s analysts see 1.72 % EPS growth. The stock increased 0.02% or $0.01 during the last trading session, reaching $48.55. About 1.31 million shares traded. Novo Nordisk A/S (NYSE:NVO) has declined 10.81% since January 12, 2018 and is downtrending. It has underperformed by 10.81% the S&P500.

Novo Nordisk A/S (NYSE:NVO) Ratings Coverage

Among 6 analysts covering Novo Nordisk (NYSE:NVO), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. Novo Nordisk had 6 analyst reports since October 8, 2018 according to SRatingsIntel. The stock of Novo Nordisk A/S (NYSE:NVO) earned “Hold” rating by Jefferies on Tuesday, December 11. On Monday, October 8 the stock rating was downgraded by Bank of America to “Neutral”. On Monday, November 19 the stock rating was upgraded by JP Morgan to “Overweight”.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. The company has market cap of $116.79 billion. It operates in two divisions, Diabetes and Obesity Care, and Biopharmaceuticals. It has a 19.72 P/E ratio. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, and oral anti-diabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles.

Another recent and important Novo Nordisk A/S (NYSE:NVO) news was published by which published an article titled: “Novo Nordisk Oral Semaglutide Shines In Phase 3 Clinical – Seeking Alpha” on February 26, 2018.

Novo Nordisk A/S (NYSE:NVO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.